Verismo Therapeutics, a Philadelphia, PA-based clinical-stage CAR T company, raised $7M in pre-Series A financing round.
The round was led by BRV Capital Management, joined by Ignite Innovation.
The financing will support continued advancement of the clinical trial for SynKIR-110™, a first-in-class KIR-CAR T cell immunotherapy candidate for solid tumors, and pre-clinical development of SynKIR-310, a KIR-CAR T cell immunotherapy therapeutic for blood cancer.
Led by Dr. Bryan Kim, chief executive officer, Verismo Therapeutics is developing the KIR-CAR platform, a modified NK-like receptor designed to improve persistence and efficacy against aggressive solid tumors. The KIR-CAR platform technology was developed specifically for advanced solid tumors, an area of high unmet medical need. It is on track to bring its first asset into first-in-human clinical trials in 2023.